MENU 
EQA Catalogue Groups
(Click on a colour/icon to filter calendar entries)
Clinical Genetics and Genetic Counselling
Genomic and Inherited Disorders
Haematological Neoplasms
Individual Competency Assessment
Molecular Newborn Screening
Molecular Pathology
Multidisciplinary team (MDT) working
Pharmacogenomics
Preimplantation Genetic Testing (PGT)
Reproductive Genomics
Sample Handling
Technical (Next Generation Sequencing)
Variant Classification
Viral Sequencing
Other Events
GenQA EQA Enrolment Event
GenQA EQA Distribution Event
GenQA webinar
Conference
GenQA workshop
GenQA Participant meeting
GenQA office closed
Other
| «prev September 2025 next»
| ||||||
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
| Sun 31 | Mon 1
Distribution 13 OPEN
2025 Chronic Lymphocytic Leukaemia (CLL) - OPENS Testing Period: 6 weeks
2025 Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status - OPENS Testing Period: 6 weeks
2025 Chronic Lymphocytic Leukaemia (CLL) TP53 mutation analysis - OPENS Testing Period: 6 weeks
2025 Lymphoma - OPENS Testing Period: 6 weeks | Tue 2 | Wed 3 | Thu 4 | Fri 5 | Sat 6 |
| Sun 7 | Mon 8
Distribution 14 OPEN
2025 Pregnancy loss - OPENS Testing Period: 6 weeks
2025 Prenatal constitutional Copy Number Variant (CNV) detection - OPENS Testing Period: 6 weeks
2025 Prenatal karyotyping - OPENS Testing Period: 6 weeks
2025 Preimplantation genetic testing for aneuploidies (PGT-A) - OPENS Testing Period: 6 weeks
2025 Preimplantation genetic testing for structural rearrangements (PGT-SR) - OPENS Testing Period: 6 weeks | Tue 9 | Wed 10 | Thu 11 | Fri 12 | Sat 13 |
| Sun 14 | Mon 15 | Tue 16 Clinical Impact of
Variability | Wed 17 | Thu 18 | Fri 19 | Sat 20 |
| Sun 21 | Mon 22
Distribution 15 OPEN
2025 BRCA testing for ovarian and prostate cancer - somatic - OPENS Testing Period: 8 weeks
2025 BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline - OPENS Testing Period: 8 weeks
2025 BRCA testing for prostate cancer - cfDNA - OPENS Testing Period: 8 weeks
2025 Circulating free (cf) DNA testing in lung cancer - OPENS Testing Period: 8 weeks
2025 Next Generation Sequencing (NGS) for germline CNVs (pilot) - OPENS Testing Period: Eight weeks
2025 Next Generation Sequencing (NGS) for germline SNVs and indels - OPENS Testing Period: Eight weeks
2025 Next Generation Sequencing (NGS) for somatic SNVs and indels - tumour testing only - OPENS Testing Period: Eight weeks
2025 Next Generation Sequencing (NGS) for somatic SNVs and indels - tumour with germline subtraction analysis - OPENS Testing Period: Eight weeks | Tue 23 | Wed 24 | Thu 25 | Fri 26
2025 Pharmacogenomics: Aminoglycoside ototoxicity - CLOSES
2025 Pharmacogenomics: APOE (pilot) - CLOSES
2025 Pharmacogenomics: CYP2C19 - CLOSES
2025 Pharmacogenomics: DPYD - CLOSES
2025 Pharmacogenomics: panel (pilot) - CLOSES
2025 Pharmacogenomics: TPMT and NUDT15 - CLOSES | Sat 27 |
| Sun 28 | Mon 29
Distribution 16 OPEN
2025 Cystic Fibrosis (CF) Molecular Newborn screening (bloodspots) round 3 - OPENS Testing Period: 4 weeks
2025 MCADD Molecular Newborn Screening (bloodspots) round 3 - OPENS Testing Period: 4 weeks
2025 SCID Molecular Newborn Screening (bloodspots) round 3 - OPENS Testing Period: 4 weeks
2025 Spinal Muscular Atrophy (SMA) Molecular Newborn screening (bloodspots) round 3 - OPENS Testing Period: 4 weeks
2025 Reproductive carrier screening (pilot) - OPENS Testing Period: 8 weeks | Tue 30 | Wed 1 | Thu 2 | Fri 3
2025 Trio Sequencing - Postnatal (neonatal and paediatric) - CLOSES
2025 SARS-CoV-2 sequencing - Distribution 5890 - round 2 - CLOSES | Sat 4 |
7872
NEWSLETTER SIGN UP